Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 16, 2020British Journal of DermatologyOpen Access

Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study

View Full Paper
Ask AI
Bookmark
Share

Authors

SPSandra PhilippHochschule der Polizei des Landes BrandenburgAMAlan MenterUniversity of Rome Tor VergataANArjen NikkelsUniversity of Liège

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Philipp et al. (2020) studied this question.

synapsesocial.com/papers/6aa923b115a756b5ce461f32https://doi.org/10.1111/bjd.19018
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study2015 · 230 citations
  2. 2The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use2010 · 1,058 citations
  3. 3Severe Psoriasis – Oral Therapy with a New Retinoid2009 · 2,750 citations
  4. 4Prevalence and Treatment of Psoriasis in the United Kingdom2005 · 602 citations
  5. 5Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)2017 · 66 citations